• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Chantal P. Bleeker-Rovers, Fidel J. Vos, +7 authors Wim J. G. Oyen
  • Medicine
  • European Journal of Nuclear Medicine and…
  • 2006 (First Publication: 1 May 2007)
  • PurposeSince 18F-fluorodeoxyglucose (FDG) accumulates in neoplastic cells and in activated inflammatory cells, positron emission tomography (PET) with FDG could be valuable in diagnosing patientsContinue Reading
  • Linda Heijmen, Lioe-Fee de Geus-Oei, +7 authors Hanneke W.M. van Laarhoven
  • Medicine
  • European Journal of Nuclear Medicine and…
  • 2012 (First Publication: 1 December 2012)
  • PurposeSeveral studies showed potential for monitoring response to systemic therapy in metastatic colorectal cancer patients with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET).Continue Reading
  • Marye J. Boers-Sonderen, Lioe-Fee de Geus-Oei, +4 authors Carla M.L. van Herpen
  • Medicine
  • Targeted Oncology
  • 2014 (First Publication: 1 December 2014)
  • Pegylated liposomal doxorubicin (PLD) is active in breast, endometrial, and ovarian cancer. Preclinical data suggest that the combination of PLD with a mammalian target of rapamycin (mTOR) inhibitorContinue Reading
  • Gijsbert J. Blokhuis, Chantal P. Bleeker-Rovers, Marije G. Diender, Wim J. G. Oyen, Jos M. Th. Draaisma, Lioe-Fee de Geus-Oei
  • Medicine
  • European Journal of Nuclear Medicine and…
  • 2014 (First Publication: 1 October 2014)
  • PurposeFever of unknown origin (FUO) and unexplained fever during immune suppression in children are challenging medical problems. The aim of this study is to investigate the diagnostic value ofContinue Reading
  • Linda Heijmen, Cornelis J A Punt, +9 authors H. W. M. van Laarhoven
  • Medicine
  • Investigational New Drugs
  • 2012 (First Publication: 1 August 2013)
  • SummaryClinical studies have shown that bevacizumab beyond progression to first line therapy is beneficial for overall survival in advanced stage colorectal cancer. We studied the utility of severalContinue Reading